AZNAstraZenecaSigning up patients
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Breast Cancer, Early Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 4,300 (planned)
- Started
- Mar 31, 2023
- Main results expected
- Apr 20, 2027
- Fully finished
- May 29, 2036
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive breast cancer-free survival (IBCFS)
Measured over: Up to 10 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05774951 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC